22nd Century Group Inc. XXII

22nd Century Group Inc. is a leading agricultural biotechnology company engaged in the development of technologies that alter the level of nicotine and cannabinoids in tobacco and cannabis plants. The firm’s aim is to reduce the harm caused by smoking, improving public health and wellness through plant science. The company is responsible for the development of VLN reduced nicotine content cigarettes, which contain 95% less nicotine than conventional tobacco cigarettes. Serving customers worldwide, the firm was founded in 1998 and is based in Buffalo, New York.

The company focuses on genetic engineering, gene editing, and modern plant breeding to reduce nicotine content in tobacco plants. It is also involved in the development and commercialisation of proprietary hemp and cannabis plants with valuable cannabinoid profiles and desirable agronomic traits.

Founded by Joseph Pandolfino, the firm’s mission was based on the concept that just as decaffeinated coffee and alcohol-free beer can help individuals make challenging life changes, nicotine-free cigarettes could have valuable public health and commercial applications. VLN reduced nicotine content cigarettes deliver significantly less harmful and addictive nicotine to users and can ultimately help individuals to give up smoking. 22nd Century Group Inc. trades on the NASDAQ under the ticker XXII.

Keep up to date on the latest share price changes by adding XXII stock to your eToro watchlist.